
Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand is an episode from FierceBiotech Radio. Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, a...
This episode belongs to FierceBiotech Radio.
Use the player on this page to stream the episode online.
Published Oct 15, 2015, 28:55 long, audio available.
Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.
You can listen to Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand online on Radio and Podcast. Open the player on this page to stream the available audio.
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand is an episode from FierceBiotech Radio.
This episode is 28:55 long.
This episode was published on Oct 15, 2015.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from FierceBiotech Radio when more episodes are available from the podcast feed.
You can listen to Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand on this page when the episode audio is available from the podcast feed.
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand is from FierceBiotech Radio.
Published Oct 15, 2015 and 28:55 long